Showing 10,821 - 10,840 results of 17,194 for search '(( 59 ((0 decrease) OR (a decrease)) ) OR ( 50 ((ns decrease) OR (mean decrease)) ))', query time: 0.97s Refine Results
  1. 10821
  2. 10822
  3. 10823
  4. 10824
  5. 10825
  6. 10826

    Data Sheet 1_Role of memantine in adult migraine: a systematic review and network meta-analysis to compare memantine with existing migraine preventive medications.docx by Guanglu Li (2315128)

    Published 2024
    “…Our analysis showed that memantine demonstrated the second-largest reduction in migraine days [standardized mean difference (SMD): −0.83; 95% confidence interval (CI): −1.26, −0.41 compared with placebo] and the highest 50% response rates [odds ratio (OR): 5.58, 95% CI: 1.31 to 23.69] in all studied interventions. …”
  7. 10827
  8. 10828

    Video1_One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy.mov by Daniel Seung Kim (19510291)

    Published 2024
    “…Moreover, in our center's experience, neither arrhythmia burden, nor contractility have worsened in the vast majority of patients: we note a clinically insignificant mean decrease in left ventricular ejection fraction (LVEF), with only two patients requiring temporary mavacamten discontinuance for LVEF < 50%. …”
  9. 10829

    Too much care? Increasing checkup frequencies and declining role of general practitioners in antenatal care in Norway (2010-2021) by Ragne Victoria Tonesdatter Kolaas Stauri (22476532)

    Published 2025
    “…</p> <p>Between Jan 1, 2010, and Dec 31, 2020, the mean number of antenatal checkups increased from 11.1 to 13.0, exceeding guidelines by 5.0. …”
  10. 10830
  11. 10831

    Video1_One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy.mov by Daniel Seung Kim (19510291)

    Published 2024
    “…Moreover, in our center's experience, neither arrhythmia burden, nor contractility have worsened in the vast majority of patients: we note a clinically insignificant mean decrease in left ventricular ejection fraction (LVEF), with only two patients requiring temporary mavacamten discontinuance for LVEF < 50%. …”
  12. 10832
  13. 10833

    Supplementary Material for: Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn’s Disease Patients by Kaymak T. (4870753)

    Published 2018
    “…FC decreased in these 8 patients in deep remission from 652 ± 168 μg/g stool (mean ± SE) at baseline to 24.9 ± 8.1 μg/g stool at 14 weeks. …”
  14. 10834
  15. 10835

    Nogo-66 activated mTOR-STAT3 signaling in NPCs astroglial differentiation. by Bin Wang (30851)

    Published 2013
    “…(J) Rapamycin treatment decreased the complex formation between mTOR and Stat3 in NPCs at the presence of Nogo-66. …”
  16. 10836

    Figure 2 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer by Robert J. Lake (22408833)

    Published 2025
    “…ED25, ED50, ED75, and ED100 = 25%, 50%, 75%, and 100% inhibition of viability, respectively. …”
  17. 10837

    Requirement of NF-κB activation for cytokine-mediated reductions in TEER. by Paul R. Clark (714064)

    Published 2015
    “…B: Effect of Bay11 concentration on the TNF-induced TEER decrease. ECIS analysis. X-axis: Duration of 0.8 ng/ml TNF treatment. …”
  18. 10838

    Influence of MCD and simvastatin on NT formation between HPMCs. by Julia Ranzinger (190489)

    Published 2011
    “…Incubation of cells with 1 nM rapamycin led to a significant decrease of NT numbers (white bar) whereas incubation with 50 µM simvastatin resulted in a strong increase (black bar). …”
  19. 10839

    Bias risk assessment of included studies. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  20. 10840

    Forest plot for hs-CRP. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”